Golding Allan, Shively Dana, Bimston David N, Harrell R Mack
Department of Endocrine Surgery, Memorial Hospital System, Hollywood, FL, USA.
The Department of Undergraduate Studies, The University of Florida, Gainesville, FL, USA.
Int J Surg Oncol. 2017;2017:4689465. doi: 10.1155/2017/4689465. Epub 2017 Apr 13.
. Retrospective studies have found that noninvasive encapsulated follicular variant of papillary thyroid cancer (EFVPTC) exhibits highly indolent clinical behavior. We studied the clinical features of our patients with noninvasive EFVPTC tumors culled from a community endocrine surgical practice registry over the past four years. . We interrogated the Memorial Center for Integrative Endocrine Surgery (MCIES) Registry for all recorded encapsulated follicular variant of papillary cancer pathologic diagnoses. We identified a subgroup of patients without capsular or vascular invasion and studied their clinical characteristics. . Thirty-seven patients met inclusion and exclusion criteria. The typical patient was young and female. Nodules averaged 3.1 cm in greatest dimension by ultrasound evaluation. Thirteen patients were found to have synchronous malignancies elsewhere in the thyroid (35%). At the time of this writing, we have not seen a clinical recurrence in any of our 37 noninvasive EFVPTC patients. . Early clinical follow-up data suggests that the majority of noninvasive EFVPTC tumors exhibit indolent behavior, but clinical decision-making with regard to completion thyroidectomy, central lymph node dissection, and adjunctive radioiodine therapy often depends on the amount and type of synchronous thyroid cancer detected elsewhere in the thyroid gland and the central neck.
回顾性研究发现,甲状腺乳头状癌的非侵袭性包膜滤泡变体(EFVPTC)表现出高度惰性的临床行为。我们研究了过去四年从社区内分泌外科实践登记处挑选出的非侵袭性EFVPTC肿瘤患者的临床特征。我们查询了纪念综合内分泌外科中心(MCIES)登记处所有记录的包膜滤泡变体乳头状癌病理诊断。我们确定了一组无包膜或血管侵犯的患者,并研究了他们的临床特征。37名患者符合纳入和排除标准。典型患者为年轻女性。通过超声评估,结节最大直径平均为3.1厘米。13名患者被发现甲状腺其他部位存在同步性恶性肿瘤(35%)。在撰写本文时,我们的37名非侵袭性EFVPTC患者中尚未出现临床复发。早期临床随访数据表明,大多数非侵袭性EFVPTC肿瘤表现出惰性行为,但关于甲状腺全切术、中央淋巴结清扫术和辅助放射性碘治疗的临床决策通常取决于在甲状腺和中央颈部其他部位检测到的同步性甲状腺癌的数量和类型。